NASDAQ:SLNO Soleno Therapeutics - SLNO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.59 -0.27 (-9.44%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.36▼$2.9250-Day Range$0.89▼$2.9152-Week Range$0.85▼$6.30Volume229,218 shsAverage Volume160,491 shsMarket Capitalization$21.13 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Soleno Therapeutics MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside208.9% Upside$8.00 Price TargetShort InterestHealthy5.95% of Float Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.47) to ($1.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector777th out of 1,025 stocksElectromedical Equipment Industry19th out of 24 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Soleno Therapeutics has a forecasted upside of 208.9% from its current price of $2.59.Amount of Analyst CoverageSoleno Therapeutics has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.95% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soleno Therapeutics has recently decreased by 55.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSoleno Therapeutics does not currently pay a dividend.Dividend GrowthSoleno Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSoleno Therapeutics has received a 72.87% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for genetic diseases" and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Soleno Therapeutics is -0.81. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Soleno Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 6 people have searched for SLNO on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -93% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Soleno Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders28.80% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Soleno Therapeutics are expected to decrease in the coming year, from ($0.47) to ($1.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soleno Therapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soleno Therapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoleno Therapeutics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Soleno Therapeutics (NASDAQ:SLNO) StockSoleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The firm focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.Read More Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLNO Stock News HeadlinesJanuary 30, 2023 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)January 29, 2023 | reuters.comSLNO.OQ - | Stock Price & Latest News | ReutersFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 26, 2023 | finance.yahoo.comSoleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi SyndromeDecember 20, 2022 | msn.comPeering Into Soleno Therapeutics's Recent Short InterestDecember 19, 2022 | marketwatch.comSoleno Therapeutics Shares Double After Financing CommitmentDecember 19, 2022 | markets.businessinsider.comWhy Is Soleno Therapeutics (SLNO) Stock Up 130% Today?December 19, 2022 | marketwatch.comThinking about buying stock in Mullen Automotive, Soleno Therapeutics, Agrify, AMC Entertainment, or Amyris?February 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 19, 2022 | finance.yahoo.comSoleno Therapeutics Announces Financing Commitment for up to $60 MillionNovember 9, 2022 | finance.yahoo.comSoleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsOctober 3, 2022 | finance.yahoo.comSoleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi SyndromeSeptember 22, 2022 | finance.yahoo.comFeneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss DrugSeptember 7, 2022 | finance.yahoo.comIronwood's (IRWD) Functional Constipation Study in Kids SucceedsSeptember 6, 2022 | finance.yahoo.comSoleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 21, 2022 | reuters.comSoleno Therapeutics IncJuly 20, 2022 | finance.yahoo.comSoleno Shares Surge On Regulatory Update For Its Prader-Willi Syndrome HopefulJuly 20, 2022 | finance.yahoo.comSoleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi SyndromeJuly 11, 2022 | finance.yahoo.comSoleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation ConferenceJuly 6, 2022 | finance.yahoo.com4 Small Stocks to Bet on in an Upbeat Drugs IndustryJune 14, 2022 | finance.yahoo.comWhy Soleno Therapeutics Shares Are Surging TodayJune 13, 2022 | seekingalpha.comSoleno Therapeutics surges on positive data from Prader-Willi syndrome treatmentJune 13, 2022 | finance.yahoo.comSoleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWSJune 7, 2022 | finance.yahoo.comSoleno Therapeutics Announces Presentations at ENDO 2022May 19, 2022 | finance.yahoo.comSoleno Therapeutics Announces Presentations at the 2022 European Congress of EndocrinologyMay 17, 2022 | finance.yahoo.comSoleno Therapeutics to Participate in the H.C. Wainwright Global Investment ConferenceMay 2, 2022 | finance.yahoo.comSoleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi SyndromeSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLNO Company Calendar Last Earnings11/09/2022Today2/05/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLNO CUSIPN/A CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees17Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+208.9%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($3.3088) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,910,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-124.06% Return on Assets-67.34% Debt Debt-to-Equity RatioN/A Current Ratio2.80 Quick Ratio2.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book0.78Miscellaneous Outstanding Shares8,160,000Free Float5,809,000Market Cap$21.13 million OptionableNot Optionable Beta0.12 Key ExecutivesAnish BhatnagarPresident, Chief Executive Officer & DirectorJames H. MackanessChief Financial OfficerKristen YenVice President-Clinical OperationsMichael WoloschakVice President-Clinical DevelopmentHarish RavivarapuVice President-Technical OperationsKey CompetitorselectroCoreNASDAQ:ECORVivani MedicalNASDAQ:VANIENDRA Life SciencesNASDAQ:NDRAHelius Medical TechnologiesNASDAQ:HSDTTivic Health SystemsNASDAQ:TIVCView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 1,914,720 shares on 11/15/2022Ownership: 1.484%State Street CorpSold 216,293 shares on 11/15/2022Ownership: 0.189%Worth Venture Partners LLCSold 1,477,191 shares on 11/14/2022Ownership: 1.293%Renaissance Technologies LLCSold 505,177 shares on 11/14/2022Ownership: 0.551%Wolverine Trading LLCSold 10,100 shares on 11/14/2022Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SLNO Stock - Frequently Asked Questions What is Soleno Therapeutics' stock price forecast for 2023? 0 Wall Street analysts have issued 12 month target prices for Soleno Therapeutics' stock. Their SLNO share price forecasts range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 208.9% from the stock's current price. View analysts price targets for SLNO or view top-rated stocks among Wall Street analysts. How have SLNO shares performed in 2023? Soleno Therapeutics' stock was trading at $1.98 on January 1st, 2023. Since then, SLNO stock has increased by 30.8% and is now trading at $2.59. View the best growth stocks for 2023 here. Are investors shorting Soleno Therapeutics? Soleno Therapeutics saw a decrease in short interest in January. As of January 15th, there was short interest totaling 265,400 shares, a decrease of 55.1% from the December 31st total of 590,900 shares. Based on an average daily trading volume, of 1,940,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 6.0% of the shares of the company are sold short. View Soleno Therapeutics' Short Interest. When is Soleno Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our SLNO earnings forecast. How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) issued its quarterly earnings data on Wednesday, November, 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.29. When did Soleno Therapeutics' stock split? Soleno Therapeutics shares reverse split on the morning of Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD). What is Soleno Therapeutics' stock symbol? Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO." Who are Soleno Therapeutics' major shareholders? Soleno Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness and William G Harris. View institutional ownership trends. How do I buy shares of Soleno Therapeutics? Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Soleno Therapeutics' stock price today? One share of SLNO stock can currently be purchased for approximately $2.59. How much money does Soleno Therapeutics make? Soleno Therapeutics (NASDAQ:SLNO) has a market capitalization of $21.13 million. The company earns $-30,910,000.00 in net income (profit) each year or ($3.3088) on an earnings per share basis. How can I contact Soleno Therapeutics? Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The official website for the company is www.soleno.life. The company can be reached via phone at (650) 213-8444, via email at ir@soleno.life, or via fax at 650-213-8383. This page (NASDAQ:SLNO) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.